InSite Vision (ISV) Initiates Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain After Cataract Surgery
5/10/2013 10:05:17 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. This study will seek to enroll approximately 240 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite against the DuraSite vehicle alone. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite drug delivery technology.
Help employers find you! Check out all the jobs and post your resume.